Biologics are therapeutic proteins, which have transformed human medicine in recent decades thanks to advances in biotechnology. They are distinct from chemically synthesized small molecule pharmaceuticals. Biologics include major categories such as mAbs, receptor fusion proteins and hormone therapies.
We believe we are the only clinical stage animal health company completely focused on bringing a 100% species-specific biologics portfolio to market.
In human medicine, the introduction of biologics, specifically mAbs, overcame many issues associated with small molecule-based therapeutics, and have now grown to be the largest class of therapeutics within the top ten best-selling drugs in humans. Six of 2013’s top ten best-selling human drugs were biologics (5 mAbs and one fusion protein), which collectively amounted to worldwide sales in 2013 of $49.1 billion. We believe that mAbs will drive a similar trend in the companion animal therapeutics market.
There has been very limited activity in therapeutic veterinary biologics compared to human medicine, with only a small number of marketing approvals issued in the U.S. or EU. We believe this creates a significant opportunity for us to develop first-in-class therapeutics for the unmet medical needs of companion animals utilizing our proprietary PETization platform. We believe a number of factors have prevented mAbs from reaching the animal health market, which PETization can address: